Skip to content
Cardiovascular Risk

ASCVD 10-Year Risk Calculator (Pooled Cohort Equations)

Estimate 10-year risk of a first hard atherosclerotic cardiovascular event — myocardial infarction, coronary death, or stroke — using the 2013 ACC/AHA Pooled Cohort Equations, for adults aged 40–79 without established cardiovascular disease.

The ASCVD risk calculator uses the 2013 ACC/AHA Pooled Cohort Equations to estimate 10-year risk of a first hard cardiovascular event in adults aged 40–79 without prior cardiovascular disease. The 2026 ACC/AHA dyslipidaemia guideline now recommends the newer PREVENT calculator as the preferred tool, but ASCVD remains useful for historical comparison, legacy guideline reference, and continuity in patients previously stratified with it.

SI Units (mmol/L) US Units (mg/dL)
Demographics
Enter age between 40 and 79
The Pooled Cohort Equations were derived in White and African American cohorts. For other ethnicities, use the "White or Other" pathway with caution — risk may be over- or under-estimated.
Clinical Parameters
Enter value between 1 and 15 mmol/L
Enter value between 0.3 and 5 mmol/L
Enter value between 80 and 250 mmHg
Please complete all required fields
10-Year ASCVD Risk
-- %
--
Estimated 10-year risk of a first hard ASCVD event (MI, coronary death, or stroke)
Low
<5%
Borderline
5–<7.5%
Intermediate
7.5–20%
High
>20%

What Is the ASCVD Risk Calculator?

The ASCVD risk calculator estimates an individual's 10-year risk of a first major cardiovascular event using the Pooled Cohort Equations developed by the American College of Cardiology and American Heart Association in 2013. It applies to adults aged 40–79 years without established cardiovascular disease.

The calculator predicts the probability of a hard ASCVD event over the next 10 years, defined as non-fatal myocardial infarction, coronary heart disease death, or fatal or non-fatal stroke. It was the guideline-recommended risk estimator for over a decade and remains widely referenced in clinical practice.

In 2024, the AHA released the PREVENT equations as a contemporary replacement, and the 2026 ACC/AHA dyslipidaemia guideline now recommends PREVENT as the preferred tool. ASCVD remains useful for historical comparison, legacy guideline reference, and continuity in patients previously stratified with the older model.

Risk Categories

The 2018 AHA/ACC cholesterol guideline defines four ASCVD risk categories based on the 10-year risk estimate, each with distinct treatment implications:

  • Low risk: <5% — Lifestyle counselling. Statin therapy generally not indicated unless a risk-enhancing factor is present.
  • Borderline risk: 5% to <7.5% — Discuss risk-enhancing factors. A moderate-intensity statin may be considered if enhancers are present.
  • Intermediate risk: 7.5% to ≤20% — Moderate-intensity statin recommended after a clinician–patient risk discussion. CAC scoring may refine the decision in selected patients.
  • High risk: >20% — High-intensity statin recommended to achieve ≥50% LDL-C reduction.

These thresholds differ from those used with the newer PREVENT model, which uses lower numerical thresholds because it produces lower numerical risk estimates than the older equations — reflecting more accurate calibration to contemporary cardiovascular event rates.

Limitations of the Pooled Cohort Equations

The Pooled Cohort Equations were derived from US cohorts collected primarily in the 1990s and early 2000s, including ARIC, CHS, CARDIA, and Framingham Offspring. Several important limitations of this calculator are now recognised:

  • Risk may be overestimated in contemporary populations because cardiovascular event rates have declined since the derivation cohorts.
  • The equations were derived only in White and African American populations; performance in other ethnicities is less well validated.
  • The model does not incorporate kidney function, body mass index, or HbA1c — known modifiers of cardiovascular risk.
  • Heart failure is not included as an outcome.
  • The model uses race as a predictor, which is now widely considered a problematic proxy for unmeasured social and biological factors.

The newer PREVENT equations address several of these limitations by removing race as a variable, incorporating kidney and metabolic measures, and including heart failure as an outcome.

Role of Coronary Artery Calcium (CAC) Scoring

In borderline and intermediate-risk patients, the ASCVD calculator alone may not provide enough certainty to guide statin therapy decisions. Coronary artery calcium (CAC) scoring offers a direct measure of subclinical atherosclerosis and can substantially refine risk in this group.

The 2018 cholesterol guideline supports the use of CAC scoring as a tie-breaker in:

  • Borderline-risk patients (5% to <7.5%) with risk-enhancing factors
  • Intermediate-risk patients (7.5% to <20%) where the statin decision is uncertain

A CAC score of zero in these patients generally supports deferring statin therapy in the absence of other compelling indications such as smoking, diabetes, or a strong family history of premature coronary disease. A CAC score above 100 — or above the 75th percentile for age, sex, and ethnicity — favours statin initiation regardless of the calculated ASCVD risk.

The MESA CAC calculator incorporates CAC into the 10-year risk estimate directly, and the CAC percentile calculator contextualises a raw CAC number by age, sex, and ethnicity.

References
  1. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–S73. doi:10.1161/01.cir.0000437741.48606.98
  2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082–e1143. doi:10.1161/CIR.0000000000000625
  3. Arnett DK, Blumenthal RS, Fonarow GC, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol. 2019;74(10):e177–e232. doi:10.1016/j.jacc.2019.03.010
  4. Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the AHA PREVENT Equations. Circulation. 2024;149(6):e430–e449. doi:10.1161/CIRCULATIONAHA.123.067626
  5. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e00–e00. doi:10.1161/CIR.0000000000001423